NEW YORK (GenomeWeb News) — Warnex today said Novartis has hired it to perform bioanalytical and pharmacogenetic services for the drug maker’s leukemia and intestinal tumors program.

Warnex said its Bioanalytical Services division will use its liquid chromatography and mass spec technologies to test blood levels of Novartis’ drug Gleevec to “help identify non-adherence or suboptimal dosing.”

Warnex also will perform PCR-based diagnostic tests to determine if patients have chromosomal abnormalities.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.

A phylogenetic analysis indicates two venomous Australian spiders are more closely related than thought, the International Business Times reports.

In Science this week: CRISPR-based approach for recording cellular events, and more.

A new company says it will analyze customers' genes to find them a suitable date, though Smithsonian magazine says the science behind it might be shaky.